Literature DB >> 6245781

Lymph node invasion and prognosis in nephroblastoma.

B Jereb, M F Tournade, J Lemerle, P A Voûte, J F Delemarre, L Ahstrom, R Flamant, R Gérard-Marchant, B Sandstedt.   

Abstract

Five hundred and twelve children with Wilms' tumor Stages I, II, and III registered to the International Society of Pediatric Oncology (SIOP) nephroblastoma trial were analyzed as to the prognostic value of metastatic lymph node involvement. The lymph nodes of 300 patients were submitted for microscopic examination; malignant invasion was reported in 15%. The disease-free and the actuarial survival rates for patients with metastatic lymph node invasion were significantly worse than for those without metastatic lymph node involvement. Radical lymph node dissection neither improved the cure rate nor decreased the rate of abdominal recurrence in patients with lymph node metastases.

Entities:  

Mesh:

Year:  1980        PMID: 6245781     DOI: 10.1002/1097-0142(19800401)45:7<1632::aid-cncr2820450719>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.

Authors:  Y Oda; I Röse; K Radig; W Wagemann; U Mittler; A Roessner
Journal:  Virchows Arch       Date:  1997-02       Impact factor: 4.064

2.  Lymph node involvement in Wilms tumor: results from National Wilms Tumor Studies 4 and 5.

Authors:  Kathleen Kieran; James R Anderson; Jeffrey S Dome; Peter F Ehrlich; Michael L Ritchey; Robert C Shamberger; Elizabeth J Perlman; Daniel M Green; Andrew M Davidoff
Journal:  J Pediatr Surg       Date:  2012-04       Impact factor: 2.545

3.  [Risk factors for intra- and postoperative complications in Wilms' tumor surgery].

Authors:  V Zugor; D Krot; G E Schott
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

4.  Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4.

Authors:  R C Shamberger; K A Guthrie; M L Ritchey; G M Haase; J Takashima; J B Beckwith; G J D'Angio; D M Green; N E Breslow
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

5.  Inter-rater reliability of surgical reviews for AREN03B2: a COG renal tumor committee study.

Authors:  Thomas E Hamilton; Douglas Barnhart; Kenneth Gow; Fernando Ferrer; Jessica Kandel; Richard Glick; Roshni Dasgupta; Arlene Naranjo; Ying He; Eric Gratias; James Geller; Elizabeth Mullen; Peter Ehrlich
Journal:  J Pediatr Surg       Date:  2013-10-05       Impact factor: 2.545

6.  Stage II neuroblastoma. Adverse prognostic significance of lymph node involvement.

Authors:  J Ninane; J Pritchard; P H Morris Jones; J R Mann; J S Malpas
Journal:  Arch Dis Child       Date:  1982-06       Impact factor: 3.791

Review 7.  Wilms tumour: prognostic factors, staging, therapy and late effects.

Authors:  Sue C Kaste; Jeffrey S Dome; Paul S Babyn; Norbert M Graf; Paul Grundy; Jan Godzinski; Gill A Levitt; Helen Jenkinson
Journal:  Pediatr Radiol       Date:  2007-11-17

Review 8.  Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol.

Authors:  Saskia L Gooskens; Norbert Graf; Rhoikos Furtwängler; Filippo Spreafico; Christophe Bergeron; Gema L Ramírez-Villar; Jan Godzinski; Christian Rübe; Geert O Janssens; Gordan M Vujanic; Ivo Leuschner; Aurore Coulomb-L'Hermine; Anne M Smets; Beatriz de Camargo; Sara Stoneham; Harm van Tinteren; Kathy Pritchard-Jones; Marry M van den Heuvel-Eibrink
Journal:  Nat Rev Urol       Date:  2018-02-27       Impact factor: 14.432

9.  Use of nephron sparing surgery and impact on survival in children with Wilms tumor: a SEER analysis.

Authors:  Hsin-Hsiao S Wang; Michael R Abern; Nicholas G Cost; David I Chu; Sherry S Ross; John S Wiener; Jonathan C Routh
Journal:  J Urol       Date:  2014-04-13       Impact factor: 7.450

Review 10.  The current status of treatment of Wilms' tumor as per the SIOP trials.

Authors:  Jan Godzinski
Journal:  J Indian Assoc Pediatr Surg       Date:  2015-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.